Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

Protein levels were measured in cerebrospinal fluid samples (CSF; n = 186) and plasma samples (n = 165) from persons with multiple sclerosis and healthy controls. CSF samples and plasma samples were taken from 92 persons with CIS or RRMS at Linköping University Hospital, Sweden and 51 persons with CIS or RRMS at the Karolinska University Hospital, Sweden. Everyone fulfilled the revised McDonald criteria from 2010 and 2017 for CIS or Multiple sclerosis (MS). Age-matched healthy controls (HC) were recruited from healthy blood donors (23 at the Linköping University hospital and 20 at the Karolinska University Hospital). The concentration of 1463 proteins were measured using the Olink Explore platform which uses Proximity Extension Assay (PEA) technology. The proteins were preselected from four Olink panels: Explore 384 Cardiometabolic, Explore 384 Inflammation, Explore 384 Neurology, and Explore 384 Oncology. The protein concentrations are given as Olink’s relative protein quantification unit on log2 scale: Normalized Protein Expression (NPX). The NPX values were intensity normalized by Olink. Raw data: supplementary information to publication For access to dataset, please contact [e-mail] for further information. Research funders: Swedish Foundation for Strategic Research (SB16-0011) Swedish Brain Foundation Knut and Alice Wallenberg Foundation Margareth AF Ugglas Foundation Swedish Research Council (2019-04193, 2018-02776, 2020-02700, 2021-03092) Swedish Knowledge Foundation (2020-0014) Medical Research Council of Southeast Sweden (FORSS-315121) NEURO Sweden (F2018-0052) ALF grants Region Östergötland Swedish Foundation for MS Research European Union's Marie Sklodowska-Curie (813863) The dataset was originally published in DiVA and moved to SND in 2024.本数据集针对多发性硬化症（Multiple Sclerosis, MS）患者与健康对照人群的脑脊液（CSF）样本（n=186）及血浆样本（n=165）开展蛋白质水平定量检测。其中92名临床孤立综合征（Clinical Isolated Syndrome, CIS）或复发缓解型多发性硬化（Relapsing-Remitting Multiple Sclerosis, RRMS）患者招募自瑞典林雪平大学医院，另有51名同类患者招募自瑞典卡罗林斯卡大学医院，所有受试者均符合2010年与2017年修订的、针对临床孤立综合征与多发性硬化的麦克唐纳（McDonald）诊断标准。年龄匹配的健康对照（Healthy Controls, HC）招募自健康献血者群体，其中23名来自林雪平大学医院，20名来自卡罗林斯卡大学医院。 本研究采用Olink Explore检测平台（依托邻近延伸分析法（Proximity Extension Assay, PEA）技术）对1463种蛋白质的浓度进行定量。所选蛋白质来自4款Olink检测面板：Explore 384心血管代谢面板、Explore 384炎症面板、Explore 384神经科学面板及Explore 384肿瘤学面板。蛋白质浓度以Olink相对蛋白质定量单位——归一化蛋白质表达量（Normalized Protein Expression, NPX）表示，取值基于log2对数尺度；NPX值已由Olink完成强度归一化处理。 原始数据详见该研究的补充材料。如需获取本数据集，请联系邮箱[e-mail]咨询详情。 本研究受以下机构资助：瑞典战略研究基金会（SB16-0011）、瑞典脑基金会、克努特与爱丽丝·瓦伦堡基金会、Margareth AF Ugglas基金会、瑞典研究理事会（2019-04193、2018-02776、2020-02700、2021-03092）、瑞典知识基金会（2020-0014）、瑞典东南地区医学研究理事会（FORSS-315121）、瑞典神经科学协会（NEURO Sweden, F2018-0052）、ALF资助项目、东约特兰地区、瑞典多发性硬化研究基金会以及欧盟玛丽·居里奖学金项目（813863）。 本数据集最初发表于DiVA数据库，并于2024年迁移至瑞典国家数据服务中心（SND）。